|
Advertising
Customer Service
• Register
|
MORE FROM NJBIZ
PEOPLE WHO READ THIS...
Also read these stories:
 Related Articles
This Week's Most Read Articles
Most Recent Articles
|
|||||||||
By Evelyn Lee
Under terms of the agreement, Ranbaxy, an Indian pharmaceutical company whose U.S. headquarters are in Princeton, will have a license to sell generic versions of atorvastatin and the fixed-dose combination of atorvastatin-amlodipine besylate in the United States beginning Nov. 30, 2011. Because Ranbaxy was the first generic pharmaceutical company to challenge the Lipitor patents, it retains the right to marketing exclusivity for 180 days in the United States, according to the firm.
Ranbaxy says it will also have a license to sell atorvastatin on varying dates in an additional seven countries, including Canada, Belgium, Netherlands, Germany, Sweden, Italy and Australia. Ranbaxy and Pfizer said they have also resolved their disputes regarding atorvastatin in Malaysia, Brunei, Peru and Vietnam.
